World-first: therapy to make cells young again trialled in a person

A participant in a clinical trial received a cellular-reprogramming therapy on June 9, 2026, marking the first human trial of a treatment designed to reverse cellular aging in damaged eye cells. This groundbreaking therapy, detailed in a publication by Nature, utilizes a process known as cellular reprogramming, which aims to revert cells to a more youthful state. The trial focuses on treating age-related macular degeneration (AMD), a leading cause of vision loss in older adults. Previous research in animal models demonstrated that this reprogramming technique could restore youthful function to aged cells without causing them to become cancerous or lose their identity. The therapy involves delivering specific reprogramming factors to the target cells, prompting them to shed age-related markers and regain regenerative capabilities. If successful, this approach could offer a novel treatment for AMD and potentially other age-related diseases by addressing the fundamental aging processes within cells. The trial's success hinges on demonstrating both the safety and efficacy of this rejuvenation technique in humans, a critical step towards translating laboratory findings into clinical applications.